<DOC>
	<DOC>NCT00670189</DOC>
	<brief_summary>The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule</brief_summary>
	<brief_title>A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Basal Cell</mesh_term>
	<criteria>For additional information, please contact the BMS oncology clinical trial information service at 8552160126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation. Advanced or metastatic cancer (excluding cancer in the blood) or uncontrolled basal cell nevoid syndrome or sporadic basal cell carcinoma Primary or metastatic tumor site accessible for biopsy Ability to swallow capsules Subjects with histologically confirmed, advanced stage IIIB or stage IV nonsmall cell lung cancer (NSCLC) with a primary histology of squamous carcinoma who have received prior systemic therapy for advanced NSCLC will be enrolled in Part 3 Uncontrolled brain metastasis Significant cardiovascular disease Inadequate blood counts Inadequate liver, kidney or lung function Gastrointestinal disease within last 3 months Infection with Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C or exposure to attenuated active immunizations</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>